- Home
- ARWR vs IDYA Comparison
ARWR vs IDYA Comparison
Compare ARWR & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARWR
- IDYA
- Stock Information
- Founded
- ARWR 2003
- IDYA 2015
- Country
- ARWR United States
- IDYA United States
- Employees
- ARWR N/A
- IDYA N/A
- Industry
- ARWR Biotechnology: Pharmaceutical Preparations
- IDYA Biotechnology: Pharmaceutical Preparations
- Sector
- ARWR Health Care
- IDYA Health Care
- Exchange
- ARWR Nasdaq
- IDYA Nasdaq
- Market Cap
- ARWR 1.8B
- IDYA 1.5B
- IPO Year
- ARWR 1993
- IDYA 2019
- Fundamental
- Price
- ARWR $16.07
- IDYA $19.89
- Analyst Decision
- ARWR Buy
- IDYA Strong Buy
- Analyst Count
- ARWR 10
- IDYA 12
- Target Price
- ARWR $42.13
- IDYA $54.27
- AVG Volume (30 Days)
- ARWR 1.9M
- IDYA 1.5M
- Earning Date
- ARWR 05-12-2025
- IDYA 05-06-2025
- Dividend Yield
- ARWR N/A
- IDYA N/A
- EPS Growth
- ARWR N/A
- IDYA N/A
- EPS
- ARWR N/A
- IDYA N/A
- Revenue
- ARWR $545,209,000.00
- IDYA $7,000,000.00
- Revenue This Year
- ARWR $4,380.43
- IDYA $68.39
- Revenue Next Year
- ARWR $66.56
- IDYA $324.54
- P/E Ratio
- ARWR N/A
- IDYA N/A
- Revenue Growth
- ARWR 1436.97
- IDYA N/A
- 52 Week Low
- ARWR $9.57
- IDYA $13.45
- 52 Week High
- ARWR $30.41
- IDYA $44.42
- Technical
- Relative Strength Index (RSI)
- ARWR 59.58
- IDYA 58.60
- Support Level
- ARWR $14.92
- IDYA $19.26
- Resistance Level
- ARWR $17.19
- IDYA $20.46
- Average True Range (ATR)
- ARWR 0.95
- IDYA 0.97
- MACD
- ARWR 0.11
- IDYA 0.17
- Stochastic Oscillator
- ARWR 70.29
- IDYA 84.25
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.